Aldosterone antagonists - Last man standing?

New England Journal of Medicine

Volumn 364, Issue 1, 2011, Pages 79-80

  Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; SPIRONOLACTONE; WARFARIN;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; DEFIBRILLATOR; DISEASE ASSOCIATION; DRUG USE; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE NECROSIS; HOSPITALIZATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 78650886292     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1012547     Document Type: Editorial

References (10)

1. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77.
2. Selye H. Protection by a steroid-spironolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 1960; 104:212-3.
3. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
6. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119(14):e391-e479. [Erratum, Circulation 2010;121(12):e258.]
7. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
8. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-65.
9. Wei L, Struthers AD, Fahey T, Watson AD, MacDonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010;340:c1768.
10. Tomaschitz A, Pilz S, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010;31:1237-47.